Antibodies

11 July 2016

AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)

9 July 2016

Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases

8 July 2016

Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031

8 July 2016

FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma in Children

7 July 2016

New Data from Phase 3 REGAIN Study of Eculizumab (Soliris(R)) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress

7 July 2016

AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress

7 July 2016

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

7 July 2016

Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma

7 July 2016

Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

7 July 2016

Ablynx announces positive topline results from a phase IIb study of its anti-il-6R nanobody, vobarilizumab (ALX-0061), as a monotherapy in RA

5 July 2016

Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis

1 July 2016

GSK announces start of phase I oncology study with its ICOS agonist antibody

1 July 2016

AbbVie’s HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

1 July 2016

Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer

30 June 2016

Leap Therapeutics Presents Positive Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer

30 June 2016

BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317

29 June 2016

Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial

28 June 2016

Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia

28 June 2016

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

28 June 2016

XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213

28 June 2016

FDA Grants Priority Review for Genentech’s OCREVUS™ (Ocrelizumab) Biologics License Application

27 June 2016

Hetero Launches Biosimilar ‘Bevacizumab’ for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name ‘Cizumab™’

27 June 2016

Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

27 June 2016

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer

24 June 2016

Teva Receives CHMP Positive Opinion for CINQAERO® (reslizumab)

24 June 2016

Genmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL

23 June 2016

Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550

22 June 2016

Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program

22 June 2016

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors

22 June 2016

ASM Microbe 2016 Presentation of Clinical Results From CytoDyn’s Phase 2b Monotherapy Extension Study Now Available

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD73 Inhibitor Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

EpCAM-Targeted Antibodies Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases